Go­ing deep­er in­to the ezce­ma game, No­var­tis or­ches­trates $1.1B deal for a Mor­phoSys/Gala­pa­gos drug

A busy busi­ness de­vel­op­ment team at No­var­tis has made der­ma­tol­ogy the fo­cus of their lat­est bil­lion-dol­lar deal.

The cho­sen drug is MOR106, an IL-17C mon­o­clon­al an­ti­body de­vel­oped by the part­ner­ship be­tween Mor­phoSys $MOR and Gala­pa­gos $GLPG. In ex­change for giv­ing up all de­vel­op­ment and mar­ket­ing rights, the duo will be split­ting $111 mil­lion (€95 mil­lion) up­front and pen­cil­ing in po­ten­tial mile­stone pay­ments to­tal­ing $1 bil­lion (€850 mil­lion).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER